AR and prostate cancer: Proteasomal degradation of TM4SF3, in contrast to AR and AR-V7, was unknown until our two recent studies, showing that MG132 can block TM4SF3 degradation in prostate cancer cells (Bhansali et al. 2016), and demonstrated TM4SF3 in vitro ubiquitination that is inhibited by association with either AR or AR-V7 (Khatiwada et al. 2023).